Immunocore Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma
Immunocore宣佈第一名患者被隨機分組參加全球，註冊階段3臨床試驗，測試Brenetafusp治療一線晚期或轉移性皮膚黑素瘤